Updated Efficacy and Safety of Lenvatinib Plus Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Advanced Endometrial Cancer: Study 309/KEYNOTE-775

Video

Dr Domenica Lorusso reviews data updates from KEYNOTE-775 that were recently presented at the European Society for Medical Oncology (ESMO) Congress 2022.

Related Videos
Abdulrahman Sinno, MD
Amin Nassar, MD
Rebecca L. Porter, MD, PhD
Christian Marth, MD, PhD
Christian Marth, MD, PhD
Dmitriy Zamarin, MD, PhD
Related Content
Abdulrahman Sinno, MD

Sinno Spotlights Key Clinical Trials Driving Targeted Approaches in Gynecologic Oncology

April 17th 2024
Article
Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

January 11th 2024
Podcast
Christian Marth, MD, PhD

Pembrolizumab/Lenvatinib Extends Survival in Advanced/Recurrent Endometrial Cancer Subgroups

April 15th 2024
Article
R. Wendel Naumann, MD

Naumann Discusses Notable Research Efforts in Endometrial Cancer

October 26th 2023
Podcast
Abdulrahman Sinno, MD

Improved Molecular Classification Drives Tailored Treatment Approaches in Endometrial Cancer

April 11th 2024
Article
Rebecca L. Porter, MD, PhD, of Dana-Farber Cancer Institute

Mirvetuximab Soravtansine Plus Pembrolizumab Makes a Splash in pMMR/MSS FRalpha+ Endometrial Cancer

April 9th 2024
Article